Ulcers and Gastritis

 

 Buy Article Permissions and Reprints

Significant advances continue to be made in the area of gastritis and ulcer disease. Studies to identify the most appropriate use of capsule endoscopy have now confirmed that it is superior to other methods for identifying small-bowel mucosal pathology and sites of obscure gastrointestinal bleeding. It has increasingly been recognized that the complications of ulcer disease are secondary to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and to interactions between NSAIDs and Helicobacter pylori. Effective prophylaxis for NSAID ulcers in H. pylori-negative individuals continues to be a challenge, as it has become clear that conclusions from studies focusing on ”endoscopic ulcers” in patients whose H. pylori status was unknown provided a false sense of security. The concept of multifocal atrophic gastritis has been challenged. The precursor lesion to gastric cancer now appears to be a sheet of pseudopyloric metaplasia advancing into the gastric body with islands of intestinal metaplasia embedded within it. Multifactorial models such as those proposed for understanding periodontal disease, including the organism, environmental factors, and host factors, appear particularly applicable to understanding the pathogenesis of H. pylori-associated gastric cancer.

References

• 1 Costamagna G, Shah S K, Riccioni M E. et al . A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease.  Gastroenterology. 2002;  123 999-1005
  CrossrefPubMedGoogle Scholar
• 2 Ell C, Remke S, May A. et al . The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding.  Endoscopy. 2002;  34 685-689
  Google Scholar
• 3 Scapa E, Jacob H, Lewkowicz S. et al . Initial experience of wireless-capsule endoscopy for evaluating occult gastrointestinal bleeding and suspected small bowel pathology.  Am J Gastroenterol. 2002;  97 2776-2779
  CrossrefPubMedGoogle Scholar
• 4 Mylonaki M, Fritscher-Ravens A, Swain P. Wireless capsule endoscopy: a comparison with push enteroscopy in patients with gastroscopy and colonoscopy negative gastrointestinal bleeding.  Gut. 2003;  52 1122-1126
  CrossrefPubMedGoogle Scholar
• 5 Saurin J C, Delvaux M, Gaudin J L. et al . Diagnostic value of endoscopic capsule in patients with obscure digestive bleeding: blinded comparison with video push-enteroscopy.  Endoscopy. 2003;  35 576-584
  Google Scholar
• 6 Fireman Z, Mahajna E, Broide E. et al . Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy.  Gut. 2003;  52 390-392
  Google Scholar
• 7 Liangpunsakul S, Chadalawada V, Rex D K. et al . Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis.  Am J Gastroenterol. 2003;  98 1295-1298
  CrossrefPubMedGoogle Scholar
• 8 Spiegel B M, Ofman J J, Woods K, Vakil N B. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies.  Am J Gastroenterol. 2003;  98 86-97
  CrossrefPubMedGoogle Scholar
• 9 Brunner G, Luna P, Hartmann M, Wurst W. Optimizing the intragastric pH as a supportive therapy in upper GI bleeding.  Yale J Biol Med. 1996;  69 225-231
  PubMedGoogle Scholar
• 10 Labenz J, Peitz U, Leusing C. et al . Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.  Gut. 1997;  40 36-41
  PubMedGoogle Scholar
• 11 Sung J Y, Chan F K, Lau J WW. et al . The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcer with nonbleeding visible vessels or adherent clots: a randomized comparison.  Ann Intern Med. 2003;  139 237-243
  PubMedGoogle Scholar
• 12 Huggins R M, Scates A C, Latour J K. Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding.  Ann Pharmacother. 2003;  37 433-437
  CrossrefPubMedGoogle Scholar
• 13 Lee K K, You J H, Wong I C. et al . Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer.  Gastrointest Endosc. 2003;  57 160-164
  PubMedGoogle Scholar
• 14 Lau J Y, Sung J J, Lee K K. et al . Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.  N Engl J Med. 2000;  343 310-316
  CrossrefPubMedGoogle Scholar
• 15 Sheu B S, Chi C H, Huang C C. et al . Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding.  Aliment Pharmacol Ther. 2002;  16 137-143
  PubMedGoogle Scholar
• 16 van Leerdam M E, Vreeburg E M, Rauws E A. et al . Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000.  Am J Gastroenterol. 2003;  98 1494-1499
  PubMedGoogle Scholar
• 17 Adamopoulos A, Efstathiou S, Tsioulos D. et al . Acute upper gastrointestinal bleeding: comparison between recent users and nonusers of nonsteroidal anti-inflammatory drugs.  Endoscopy. 2003;  35 327-332
  Article in Thieme ConnectPubMedGoogle Scholar
• 18 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection: the Maastricht 2 - 2000 Consensus Report.  Aliment Pharmacol Ther. 2002;  16 167-180
  PubMedGoogle Scholar
• 19 Graham D Y. NSAIDs, Helicobacter pylori, and Pandora’s box.  N Engl J Med. 2002;  347 2162-2164
  CrossrefPubMedGoogle Scholar
• 20 Chan F K, Hung L C, Suen B Y. et al . Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.  N Engl J Med. 2002;  347 2104-2110
  CrossrefPubMedGoogle Scholar
• 21 Graham D Y. Critical effect of Helicobacter pylori infection on the effectiveness of omeprazole for prevention of gastric or duodenal ulcers among chronic NSAID users.  Helicobacter. 2002;  7 1-8
  PubMedGoogle Scholar
• 22 Wallace J L, McKnight W, Del Soldato P. et al . Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.  J Clin Invest. 1995;  96 2711-2718
  PubMedGoogle Scholar
• 23 Donnelly M T, Goddard A F, Filipowicz B. et al . Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury.  Aliment Pharmacol Ther. 2000;  14 529-534
  CrossrefPubMedGoogle Scholar
• 24 Gisbert J P, Pajares J M. Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review.  Am J Gastroenterol. 2001;  96 2829-2838
  PubMedGoogle Scholar
• 25 Parente F, Maconi G, Bianchi Porro G, Caselli M. Stool test with polyclonal antibodies for monitoring Helicobacter pylori eradication in adults: a critical reappraisal.  Scand J Gastroenterol. 2002;  37 747-749
  CrossrefPubMedGoogle Scholar
• 26 Koletzko S, Konstantopoulos N, Bosman D. et al . Evaluation of a novel monoclonal enzyme immunoassay for detection of Helicobacter pylori antigen in stool from children.  Gut. 2003;  52 804-806
  CrossrefPubMedGoogle Scholar
• 27 Gosciniak G, Przondo-Mordarska A, Iwanczak B, Blitek A. Helicobacter pylori antigens in stool specimens of gastritis children before and after treatment.  J Pediatr Gastroenterol Nutr. 2003;  36 376-380
  CrossrefPubMedGoogle Scholar
• 28 El-Zimaity H M, Ota H, Graham D Y. et al . Patterns of gastric atrophy in intestinal type gastric carcinoma.  Cancer. 2002;  94 1428-1436
  CrossrefPubMedGoogle Scholar
• 29 Sipponen P, Ranta P, Helske T. et al . Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study.  Scand J Gastroenterol. 2002;  37 785-791
  PubMedGoogle Scholar
• 30 Whiting J L, Sigurdsson A, Rowlands D C. et al . The long term results of endoscopic surveillance of premalignant gastric lesions.  Gut. 2002;  50 378-381
  CrossrefPubMedGoogle Scholar
• 31 Moayyedi P, Feltbower R, Crocombe W. et al . The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group.  Aliment Pharmacol Ther. 2000;  146 719-728
  PubMedGoogle Scholar
• 32 Della M P, Lavagna A, Masoero G. et al . Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy.  Aliment Pharmacol Ther. 2002;  16 1269-1275
  CrossrefPubMedGoogle Scholar
• 33 Gene E, Calvet X, Azagra R, Gisbert J P. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.  Aliment Pharmacol Ther. 2003;  17 1137-1143
  CrossrefPubMedGoogle Scholar
• 34 Katelaris P H, Forbes G M, Talley N J, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study.  Gastroenterology. 2002;  123 1763-1769
  CrossrefPubMedGoogle Scholar
• 35 Sapone A, Vaira D, Trespidi S. et al . The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.  Am J Gastroenterol. 2003;  98 1010-1015
  CrossrefPubMedGoogle Scholar
• 36 Graham D Y, Hammoud F, El Zimaity H M. et al . Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.  Aliment Pharmacol Ther. 2003;  17 1229-1236
  CrossrefPubMedGoogle Scholar
• 37 Miehlke S, Mannes G A, Lehn N. et al . An increasing dose of omeprazole combined with amoxicillin cures Helicobacter pylori infection more effectively.  Aliment Pharmacol Ther. 1997;  11 323-329
  CrossrefPubMedGoogle Scholar
• 38 Dore M P, Graham D Y, Mele R. et al . Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.  Am J Gastroenterol. 2002;  97 857-860
  CrossrefPubMedGoogle Scholar
• 39 Gisbert J P, Calvet X, Bujanda L. et al . ”Rescue” therapy with rifabutin after multiple Helicobacter pylori treatment failures.  Helicobacter. 2003;  8 90-94
  CrossrefPubMedGoogle Scholar
• 40 Graham D Y, Opekun A R, Yamaoka Y. et al . Early events in proton pump inhibitor-associated exacerbation of corpus gastritis.  Aliment Pharmacol Ther. 2003;  17 193-200
  CrossrefPubMedGoogle Scholar
• 41 Graham D Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model.  Gastroenterology. 1997;  113 1983-1991
  PubMedGoogle Scholar
• 42 Graham D Y. Campylobacter pylori and peptic ulcer disease.  Gastroenterology. 1989;  96 615-625
  PubMedGoogle Scholar
• 43 Greenstein G, Hart T C. A critical assessment of interleukin-1 (IL-1) genotyping when used in a genetic susceptibility test for severe chronic periodontitis.  J Periodontol. 2002;  73 231-247
  CrossrefPubMedGoogle Scholar
• 44 Greenstein G, Hart T C. Clinical utility of a genetic susceptibility test for severe chronic periodontitis: a critical evaluation.  J Am Dent Assoc. 2002;  133 452-459
  PubMedGoogle Scholar
• 45 El Omar E M, Rabkin C S, Gammon M D. et al . Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.  Gastroenterology. 2003;  124 1193-1201
  CrossrefPubMedGoogle Scholar
• 46 El Omar E M, Carrington M, Chow W H. et al . Interleukin-1 polymorphisms associated with increased risk of gastric cancer.  Nature. 2000;  404 398-402
  CrossrefPubMedGoogle Scholar
• 47 El Omar E M, Carrington M, Chow W H. et al . The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer.  Nature. 2001;  412 99
  PubMedGoogle Scholar
• 48 Furuta T, El Omar E M, Xiao F. et al . Interleukin-1β polymorphisms increase risk of hypochlorhydria and atrophic gasritis and reduce risk of duodenal ulcer recurrence in Japan.  Gastroenterology. 2002;  123 92-105
  CrossrefPubMedGoogle Scholar
• 49 Kornman K, Duff G, Reilly P. Re: A critical assessment of interleukin-1 (IL-1) genotyping when used in a genetic susceptibility test for severe chronic periodontitis. Greenstein G, Hart TC (2002; 73 : 231-247).  J Periodontol. 2002;  73 1553-1556
  CrossrefPubMedGoogle Scholar

D. Y. Graham, M. D.

Veterans’ Affairs Medical Center

Room 3A-320 (111D) · 2002 Holcombe Boulevard · Houston, TX 77030 · USA

Fax: + 1-713-790-1040

Email: dgraham@bcm.tmc.edu